PaxGenBio Co., Ltd. was established in 2015 as a molecular diagnostics company that develops, manufactures, and markets a portfolio of IVD products targeting infectious diseases and cancers. PaxGenBio applies its proprietary, chimeric technologies that combine techniques for molecular and immune diagnostics. One of its original technologies, MPCR-ULFA that combines multiplex PCR amplification and universal lateral flow assay (ULFA) enables sensitive, specific, fast, affordable, and easy nucleic acid tests that are especially appropriate for applications in low resource settings. PaxGenBio pursues a world where more people live healthy lives in peace. All members are striving for the mission by developing and providing more accurate and affordable molecular diagnostic kits to more people. PaxGenBio will make best effort to listen to the opinions and valuable advice of our customers and shareholders to make better improvements for further progress and successes. We sincerely ask for your interest and support.
- MFDS approval, CE-IVD. - One-step real-time RT-PCR in a single tube. - High sensitivity and specificity. - Limit of Detection (LoD): 1 copy/µl (5 copies/rxn). - Target genes: RdRp gene and N gene. - Since the human RNase P gene is used as an internal control, it is possible to check whether the test result is accurate or not by monitoring the entire test process such as sample collection, RNA extraction, and RT-PCR. - Preventing carry-over contamination by using UDG. - User-friendly & Simple method. - Accurate diagnosis regardless of the SARS-CoV-2 Variants (Alpha, Beta, Gamma, Delta, etc.).